Figure 8

Experimental validation of immunohistochemical staining of BIRC5 and SKP2 in oure TMA cohort and their prognostic value. (A) Immunohistochemical staining of BIRC5 in the HCC TMA cohort. (B) The IRS of BIRC5 in HCC and adjacent non-cancerous tissues. ****p < 0.0001; Data are presented as the mean ± standard error of mean. (C–E) The intensities of BIRC5 immunostaining were (C) positive, (D) weakly positive and (E) negative, no strongly staining was observed in HCC tissues. Left image, magnification ×100; right image, magnification ×400; the red squares indicate the area shown in higher magnification. (F) Immunohistochemical staining of SKP2 in the HCC TMA cohort. (G) The IRS of SKP2 in HCC and adjacent non-cancerous tissues. ****p < 0.0001; Data are presented as the mean ± standard error of mean. (H–K) The intensities of SKP2 immunostaining were (H) strongly positive, (I) positive, (J) weakly positive and (K) negative. Left image, magnification ×100; right image, magnification ×400; the red squares indicate the area shown in higher magnification. (L,M) Kaplan–Meier survival curves to compare (L) OS and (M) PFI between the high-BIRC5 expression and low-BIRC5 expression patients. (N,O) Kaplan–Meier survival curves to compare (N) OS and (O) PFI between the high-SKP2 expression and low-SKP2 expression patients.